Market Place
Sourcing Support
AlzeCure to Present at Pharma Outsourcing Conference in Stockholm
27 Nov 2024 //
ACCESSWIRE
AlzeCure Pharma to Present at Redeye Life Science Day on Dec 3
26 Nov 2024 //
ACCESSWIRE
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm
20 Nov 2024 //
ACCESSWIRE
AlzeCure Publishes its Interim Report for January – Sept 2024
11 Nov 2024 //
ACCESSWIRE
AlzeCure Presents Positive TrkA-NAM Data for Osteoarthritis
28 Oct 2024 //
ACCESSWIRE
AlzeCure to Present at Partnering Conference Bioscience 2024
25 Oct 2024 //
ACCESSWIRE
AlzeCure Pharma`s CEO to Present at Redeye`s Neurology Day
17 Oct 2024 //
ACCESSWIRE
AlzeCure Broadcasts Live Event On Ph 2 Candidate For Neuropathic Pain
10 Oct 2024 //
ACCESSWIRE
AlzeCure To Present ACD856 Anti-Inflammatory Data At Alzheimer`s
01 Oct 2024 //
ACCESSWIRE
AlzeCure Publishes its Interim Report for January – June 2024
26 Aug 2024 //
ACCESSWIRE
New Article On NeuroRestore ACD856 For Alzheimer`s Published
12 Aug 2024 //
ACCESSWIRE
AlzeCure Presents New TrkA-NAM Pain Project Results At IASP 2024
07 Aug 2024 //
ACCESSWIRE
New Study Shows Positive ACD440 Results Against Neuropathic Pain
13 Jun 2024 //
ACCESSWIRE
Dr Jan Lundberg Joins Company Board After Lilly, AstraZeneca Roles
15 May 2024 //
ACCESSWIRE
AlzeCure Reports Anti-Inflammatory NeuroRestore Effects, New Patent Application
13 May 2024 //
ACCESSWIRE
AlzeCure Presents New Data Regarding the TrkA-NAM Pain Project at IASP 2024
03 Apr 2024 //
ACCESSWIRE
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856
07 Mar 2024 //
ACCESSWIRE
AlzeCure Publishes Results Supporting Development of NeuroRestore ACD856
05 Mar 2024 //
ACCESSWIRE
AlzeCure`s Alzheimer`s Project NeuroRestore ACD856 is Granted Additional Patent
29 Feb 2024 //
ACCESSWIRE
AlzeCure Publishes its Year-end Report for January - December 2023
27 Feb 2024 //
ACCESSWIRE
AlzeCure Pharma Broadcasts Live Expert Event
12 Feb 2024 //
ACCESSWIRE
AlzeCure Gets Abstract of New Preclinical Data with ACD856 Accepted
06 Feb 2024 //
ACCESSWIRE
AlzeCure Enters Next Phase of Development with TrkA-NAM ACD137
29 Jan 2024 //
ACCESSWIRE
AlzeCure Presents at Redeye Investor Forum in Göteborg on December 14
07 Dec 2023 //
ACCESSWIRE
AlzeCure Presents at Redeye Life Science Day on November 23
02 Nov 2023 //
ACCESSWIRE
AlzeCure Presents Disease-Modifying Data with NeuroRestore ACD856
25 Oct 2023 //
ACCESSWIRE
AlzeCure`s Alzheimer Project NeuroRestore ACD856 is Granted a Patent in Japan
19 Oct 2023 //
ACCESSWIRE
AlzeCure Publishes the Positive Results from the Phase I Trial of ACD856
09 Aug 2023 //
ACCESSWIRE
AlzeCure Publishes New Disease Modifying Data with NeuroRestore ACD856
11 Jul 2023 //
ACCESSWIRE
AlzeCure Presents at Aktiespararna’s Smabolagsdagarna on June 13
08 Jun 2023 //
ACCESSWIRE
LINK Medical, AlzeCure Pharma announce +ve results from ph IIa study
30 May 2023 //
PHARMIWEB
AlzeCure Announces +VE Ph IIa Study Data in Neuropathic Pain Non-opioid ACD440
24 May 2023 //
ACCESSWIRE
AlzeCure is Granted European Patent for NeuroRestore ACD856
22 May 2023 //
ACCESSWIRE
Report from the Annual General Meeting of AlzeCure Pharma on 17 May 2023
17 May 2023 //
ACCESSWIRE
AlzeCure Participates at Penser Market on May 25
16 May 2023 //
ACCESSWIRE
AlzeCure Pharma publishes its Annual Report for 2022
05 Apr 2023 //
ACCESSWIRE
AlzeCure Presents New Data at Alzheimer’s Conference AD/PD on ACD856
30 Mar 2023 //
ACCESSWIRE
AlzeCure Presents New Data on its Preventive Treatment Alzstatin at AD/PD 2023
28 Mar 2023 //
ACCESSWIRE
AlzeCure Achieves LPLV in its PII Trial of the Non-Opioid ACD440
13 Mar 2023 //
ACCESSWIRE
AlzeCure Participates at Redeye Alzheimer Seminar on March 15
07 Mar 2023 //
ACCESSWIRE
AlzeCure Publishes its Year-end Report for January - September 2022
24 Feb 2023 //
ACCESSWIRE
AlzeCure selects CD and enters next development phase with Alzstatin ACD680
12 Jan 2023 //
PHARMABIZ
AlzeCure begins Alzheimer`s therapy development phase
11 Jan 2023 //
PHARMATIMES
AlzeCure gets Abstract Accepted on New Disease-Modifying Effects of ACD856
20 Dec 2022 //
ACCESSWIRE
AlzeCure Gets Abstract on Data with Alzheimer Project Alzstatin Accepted At AD
15 Dec 2022 //
ACCESSWIRE
New Data Strengthening the Continued Clinical Develop of NeuroRestore ACD856
30 Nov 2022 //
ACCESSWIRE
AlzeCure Gets Abstract Accepted on Positive Clinical EEG Results
24 Oct 2022 //
ACCESSWIRE
AlzeCure Presents Data with Preventive Treatment Alzstatin at Conference
20 Oct 2022 //
ACCESSWIRE
AlzeCure gets Abstract Accepted on ACD856`s Indicative Disease-Modifying Effects
18 Oct 2022 //
ACCESSWIRE
AlzeCure gets new Alzheimer`s abstract accepted
18 Oct 2022 //
PHARMATIMES
AlzeCure releases results from TrkA-NAM data
22 Sep 2022 //
PHARMATIMES
AlzeCure Presents New Data on the Anti-Inflammatory Effects of its TrkA-NAM Pain
21 Sep 2022 //
ACCESSWIRE
AlzeCure`s ACD856 research shows positive impact on brain
16 Sep 2022 //
PHARMATIMES
AlzeCure`s Alzheimer’s Project NeuroRestore ACD856 Shows Positive Effect
15 Sep 2022 //
ACCESSWIRE
AlzeCure Receives US Patent for NeuroRestore ACD856
08 Sep 2022 //
ACCESSWIRE
AlzeCure Gets Abstract Accepted on Neuroprotective Effects ofNeuroRestore ACD856
30 Aug 2022 //
ACCESSWIRE
AlzeCure Publishes its Interim Report for January – June 2022
24 Aug 2022 //
ACCESSWIRE
New Review Article on AlzeCure’s NeuroRestore as a Novel Alzheimer’s Therapy
16 Aug 2022 //
ACCESSWIRE
AlzeCure Gets Abstract on New Clinical Study Data with NeuroRestore
05 Jul 2022 //
ACCESSWIRE
Positive data from clinical PI MAD study with AlzeCure`s ACD856
29 Jun 2022 //
PRNEWSWIRE
